



## REMARKS


Any fees that may be due in connection with the filing of this paper or with this application may be charged to Deposit Account No. 02-1818. If a Petition for Extension of Time is needed, this paper is to be considered such Petition. The responses filed April 23, 2010 and August 9, 2010 are incorporated by reference herein.

### Response to Office Communication Concerning Non-Responsive Amendment

In the response mailed August 9, 2010, application elected, with traverse, methods in which the capture compound is compound A set forth on page 124, where Q is biotin with a linker, X is an aryl azide, Y is an exemplary drug, an aryl sulfonamide, and Z is lysine. This is the same as subject matter elected on May 15, 2006. In the compound set forth in the Election and Response for illustrative purposes, a typographical error inadvertently was introduced in the structure of biotin

Responsive to the Notice of Non-Responsive Amendment, Applicant reiterates the election of methods that use compounds where Q is biotin with a linker, as set forth in compound A on page 124, and as illustrated correctly below:



Thus in the elected method, in the compound X is , Q comprises biotin and Z is lysine. Y, which is user selected, is a sulfonamide in an exemplary compound A. Claims 1, 2, 5, 6, 10, 17, 34, 44, 75, 110, 116, 137, 139, 140, 144, 151, 152, 160, 161, 163, 164, 166, 169 and 175 read on the elected species.

### Correction of File History

The inadvertent typographical error in the structure of biotin also was included in the previous response, mailed April 23, 2010. The compound set forth on page 24 of the

Applicant : Hubert Köster, Ph.D. *et al.*  
Serial No. : 10/760,085  
Filed : January 16, 2004


Attorney's Docket No.: 3800014.00025/2309  
**Response to Communication Concerning  
Non-Responsive Amendment**

Preliminary Amendment and Request for Continued Examination, mailed April 23, 2010, is incorrect and should comprise biotin as set forth herein above in this response.

\* \* \*

In view of the election and remarks herein, the Office respectfully is requested to resume examination on the merits.


Respectfully submitted,



---

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 3800014.00025/2309  
**Address all correspondence to:**  
Stephanie Seidman  
K&L Gates LLP  
3580 Carmel Mountain Road, Suite 200  
San Diego, California 92130  
Telephone: (858) 509-7410  
Facsimile: (858) 509-7460  
email: stephanie.seidman@klgates.com




**COPY**

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/760,085	01/16/2004	Hubert Koster	3800014.00025 / 2309	8019

77202 7590 09/03/2010  
K&L Gates LLP  
3580 Carmel Mountain Road  
Suite 200  
San Diego, CA 92130



EXAMINER

GROSS, CHRISTOPHER M

ART UNIT PAPER NUMBER

1639

MAIL DATE DELIVERY MODE

09/03/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**COMMUNICATION**

The remarks filed on 8/9/2010 is not fully responsive to the prior Office Action because applicant has not properly (ambiguously) elected a species of Q sorting function for immobilization.

On the one hand, page 1 line 6 elects Q as biotin, such as illustrated in compound A on p 124 of the present specification. On the other hand, the structure illustrated as the elected species shown on p 1 of the remarks does NOT comprise biotin in having a pyrazolo ring system rather than the imidazole found in biotin.

If applicant opts to elect Q as a pyrazolo ring, then the claim listing provided as reading on the elected species (e.g. 2, etc.) is inaccurate as well.

In response to this communication, applicant is to affirm the election of biotin or the pyrazolo structure and, if the latter, carefully consider which of the currently active claims read on the elected species and provide a substitute listing.

Since the above-mentioned reply appears to be bona fide, applicant is given ONE(1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER M. GROSS whose telephone number is (571)272-4446. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571 272 0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

**COPY**

Application/Control Number: 10/760,085

Page 3

Art Unit: 1639

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Christopher M Gross  
Examiner  
Art Unit 1639

Respectfully,

/Christopher M Gross/  
Examiner, Art Unit 1639

**COPY**